Biopharma M&A reached $84 billion in Q1 2026, the strongest start to a year since 2019, according to Dealogic data cited by Reuters. If the pace holds, total 2026 deal value could exceed $250 billion—which would rank second only to 2019, when the BMS/Celgene mega-merger drove record activity. The drivers are structural, not cyclical: the patent cliff is creating an estimated $320 billion in revenue exposure by 2030, cash reserves are deep, biotech valuations remain below 2021 highs, and a wave of positive Phase 3 readouts has created a historically deep pool of de-risked acquisition targets. Lilly alone has deployed approximately $20 billion across six deals. Gilead committed $15 billion across three. And the trend is no longer limited to mega-cap pharma. Teva Pharmaceutical announced a definitive agreement to acquire Emalex Biosciences for up to $900 million—its largest deal in a decade—adding a first-in-class dopamine D1 receptor antagonist with positive Phase 3 data in pediatric Tourette syndrome. Purdue Pharma permanently ceased operations on May 1. DDW is live in San Diego. And ASCO is four weeks out, with Revolution Medicines’ plenary session on May 31.
Top Story: The $250B M&A Year in Historical Context
What Happened: Reuters published an analysis on May 1 using Dealogic data reporting that biopharma M&A deal value hit $84 billion in Q1 2026, nearly double the $44.4 billion recorded in Q1 2025 and the strongest start to a year since 2019. If the current pace holds through Q4, total 2026 biopharma deal value could exceed $250 billion, which would be the second-highest total in history behind only 2019.
Why the Pace Is Structural
Three analysts, four investors, and a banker told Reuters the surge is “broader and more durable than just a rebound to pre-COVID years.” The structural drivers are clear and reinforcing:
The patent cliff is creating urgency at scale. An estimated $320 billion in branded pharmaceutical revenue is at risk from patent expirations through 2030. Companies cannot replace that revenue through internal R&D alone on the timelines they face. External innovation, purchased at premium prices, has become the primary growth strategy.
Cash reserves are deep. The GLP-1 boom, strong oncology franchises, and years of cash generation have left large pharma companies with substantial balance sheets. Lilly’s Q1 alone generated $7.4 billion in GAAP net income.
Biotech valuations remain attractive. Despite the recovery from 2022 lows, biotech valuations remain below 2021 peaks, making clinical-stage companies more affordable than they would have been at the top of the pandemic-era boom.
Positive Phase 3 data is creating targets. A historically strong cycle of late-stage clinical readouts—Revolution Medicines in pancreatic cancer, Kailera in obesity, Beeline in lupus, and others—has produced a pool of de-risked acquisition candidates that reduce the clinical risk buyers need to underwrite.
The Deal Pace Has Not Slowed in Q2
April alone produced a cascade of new transactions: Lilly/Kelonia (up to $7 billion), Lilly/CrossBridge (up to $300 million), Lilly/Ajax (up to $2.3 billion), Chiesi/KalVista ($1.9 billion), Teva/Emalex ($900 million), UCB/Neurona (up to $1.15 billion), and multiple licensing deals including AbbVie/Kestrel ($1.45 billion option) and Lilly/Profluent ($2.25 billion in milestones). May is setting up to be equally active, with ASCO data drops on May 31 likely to create new acquisition targets and accelerate ongoing discussions.
The Repeat Buyers
The concentration of dealmaking among a handful of companies is striking. Lilly has announced six deals totaling approximately $20 billion. Gilead committed $15 billion across three Q1 acquisitions. Merck, AbbVie, Novartis, and BMS have all been active through acquisitions, licensing deals, or option agreements. The willingness of these companies to return to the M&A table multiple times within the same quarter—Lilly most aggressively—signals that individual transactions are insufficient to address the scale of the pipeline challenge each company faces.
What $250B Would Mean
For context, Dealogic data show 2019 as the all-time record year for biopharma M&A, driven primarily by the BMS/Celgene mega-merger. A $250 billion year in 2026 would not depend on a single transformative transaction—it would be the product of sustained deal flow across dozens of mid-sized and large transactions spanning oncology, immunology, metabolic disease, cell therapy, rare disease, and neuroscience. That breadth distinguishes 2026 from previous peak years and suggests the current cycle is more durable than the mega-merger-driven spikes of the past.
BioPharma Dive separately reported that six biotech IPOs above $300 million have occurred in 2026, with two above $400 million. The combination of strong M&A premiums providing valuation benchmarks and an improving IPO environment creates a favorable capital cycle for clinical-stage biotechs.
Our Pro brief analyzes why the $250B pace is structural rather than cyclical, which companies still have the most acquisition capacity, and how the ASCO data cycle on May 31 could create the next wave of acquisition targets. [Details below.]
What to Watch
ASCO on May 31 is the next major catalyst for M&A activity. Practice-changing data presentations—particularly Revolution Medicines’ plenary session—could trigger acquisition discussions that have been waiting for clinical validation. Watch for mid-cap pharma companies (Teva, UCB, Chiesi) to continue entering the M&A market alongside the mega-cap buyers, a dynamic that broadens the buyer pool and sustains deal flow even if any single large-cap company pauses to focus on integration.
Teva Acquires Emalex for Up to $900M in Its Biggest Deal in a Decade
What Happened: Teva Pharmaceutical announced a definitive agreement on April 29 to acquire Emalex Biosciences for $700 million upfront plus up to $200 million in commercial milestones and royalties on global ecopipam net sales. Teva will fund the upfront from cash on hand. Close is expected by Q3 2026.
The Asset: First-in-Class for Pediatric Tourette Syndrome
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist being developed for pediatric Tourette syndrome. The drug has received FDA Orphan Drug and Fast Track designations. Positive Phase 3 data demonstrated a statistically significant improvement on the primary efficacy endpoint. NDA submission is anticipated in H2 2026.
The D1 receptor selectivity is the key differentiator. All currently available treatments for Tourette syndrome that target the dopamine system work primarily through D2 receptor blockade—the same mechanism used by antipsychotics. D2 blockade carries significant side-effect burdens including sedation, weight gain, and metabolic complications that limit tolerability, particularly in the pediatric population where Tourette syndrome is most prevalent. Ecopipam’s selective D1 antagonism avoids the D2 pathway entirely, offering a mechanistically differentiated treatment option with a potentially cleaner side-effect profile.
No approved treatments currently exist that selectively target the D1 receptor in Tourette syndrome.
Teva’s Transformation from Generics to Innovation
CEO Richard Francis called the deal “our Pivot to Growth strategy in action.” Jefferies analyst Dennis Ding described it as “interesting” and said it “makes sense” given the synergies between ecopipam and Teva’s existing neurology portfolio, which includes Austedo (tardive dyskinesia and Huntington’s chorea). BioPharma Dive called it Teva’s largest deal in a decade.
The acquisition fits a pattern of transformation at Teva. The company has been building a growing innovative pipeline around Austedo, Ajovy (migraine), and Uzedy (schizophrenia). Ecopipam adds a first-in-class neuroscience asset with NDA-ready Phase 3 data and a clear commercial opportunity in a rare disease population. The NDA filing in H2 2026 positions ecopipam for potential approval in 2027, giving Teva a new growth driver as it navigates the generics pricing pressures that have weighed on the company for years.
The deal also signals that mid-cap pharma is joining the M&A spree. For most of 2026, the largest deals have come from mega-cap companies: Lilly, Gilead, Merck, Biogen. Teva’s entry at $900 million, alongside UCB’s $1.15 billion Neurona deal and Chiesi’s $1.9 billion KalVista acquisition, demonstrates that the acquisition appetite extends beyond the top tier.
Our Pro brief analyzes how the Emalex deal fits Teva’s generics-to-innovation pivot, the commercial opportunity in Tourette syndrome, and the synergies with Teva’s existing neurology commercial infrastructure. [Details below.]
Industry Note: Purdue Pharma Ceases Operations
Purdue Pharma permanently ceased operations on May 1, 2026, following the conclusion of its Chapter 11 bankruptcy proceedings. Knoa Pharma began operations as an independent successor entity focused on ensuring safe access to critical medicines and supporting communities affected by the opioid crisis.
Why This Matters: The closure ends the corporate existence of one of the most controversial pharmaceutical companies in American history. Purdue’s aggressive marketing of OxyContin is widely recognized as a central catalyst of the opioid epidemic that has killed more than 500,000 Americans. The bankruptcy proceedings resulted in settlements exceeding $6 billion directed toward opioid abatement programs. Knoa Pharma’s mandate—safe access to critical medicines and community support—represents an attempt to redirect the corporate legacy toward harm reduction rather than the profit-maximization culture that defined Purdue’s final decades. The transition also serves as a reminder that pharmaceutical companies operate under a social license that can be revoked. Purdue’s dissolution is the most extreme consequence any pharmaceutical company has faced in the modern era, and it establishes a precedent that corporate misconduct in the industry can result in the termination of the corporate entity itself.
The Foundayo Launch in Context
Lilly’s Q1 earnings on April 30 provided the most comprehensive update on Foundayo’s early commercial trajectory. CEO Ricks said more than 20,000 people have started taking the drug. IQVIA data show 3,707 prescriptions in the week ending April 17, up 167% from 1,390 in the first partial week but below analyst expectations of approximately 8,000. For comparison, Novo’s oral Wegovy hit 18,410 prescriptions in its second full week.
Lilly noted that 12-plus major telehealth firms are offering Foundayo, accounting for about 35% of launch volume, and suggested that some prescriptions are being captured through channels that IQVIA may not fully track. RBC’s Trung Huynh said Weeks 8 through 12 are the “earliest window to assess Foundayo’s true commercial momentum.”
The competitive gap with oral Wegovy is real. Whether it closes depends on whether Foundayo’s convenience advantage—no food or water restrictions versus oral Wegovy’s 30-minute fasting requirement—translates into accelerating prescription volume as physician and patient awareness builds. The next four to eight weeks of TRx data will determine the narrative.
Strategic Themes
1. $84B in Q1 Makes the M&A Supercycle Official
The Reuters analysis using Dealogic data confirms what the deal flow has been signaling all year: 2026 biopharma M&A is not a normal year. It is on pace to be the second-largest deal year in the industry’s history. The breadth of activity—spanning oncology, cell therapy, rare disease, neuroscience, immunology, metabolic disease, and AI drug discovery—distinguishes this cycle from previous peaks that were driven by one or two mega-mergers. The structural drivers (patent cliff, deep cash, positive data, attractive valuations) are durable, suggesting the pace can sustain through the second half of the year.
2. Mid-Cap Pharma Is Joining the Acquisition Spree
Teva at $900 million. UCB at $1.15 billion. Chiesi at $1.9 billion. The M&A wave is no longer limited to mega-cap companies with $50 billion-plus in acquisition capacity. Mid-sized pharma companies with their own growth challenges—generic pricing pressure for Teva, franchise diversification for UCB, portfolio building for Chiesi—are entering the market as active buyers. This broadens the buyer pool and creates more transaction opportunities for clinical-stage biotechs, supporting the favorable capital environment that has driven biotech IPOs and follow-on offerings throughout the year.
3. The Foundayo-Versus-Wegovy Gap Is the Competitive Question of the Quarter
3,707 versus 18,410 in Week 2. The difference between Foundayo’s early launch trajectory and oral Wegovy’s is the most watched competitive datapoint in all of pharma. If the gap closes over the next month—driven by expanding retail pharmacy access, telehealth partnerships, and Foundayo’s no-fasting convenience advantage—the narrative shifts from “slower than expected” to “building momentum.” If the gap persists, questions about Novo’s first-mover advantage and the difficulty of launching a new brand against an established one will intensify.
4. ASCO on May 31 Is Four Weeks Out—and It Will Create the Next Wave of M&A Targets
Revolution Medicines’ plenary session with full RASolute 302 data is the headliner, but ASCO will produce data across dozens of clinical programs in oncology. Practice-changing readouts create acquisition targets. Disappointing readouts create partnership opportunities. The ASCO data cycle has historically been a catalyst for M&A discussions that close in the following months. With the deal environment already running at record pace, ASCO could accelerate it further.
Frequently Asked Questions
How much M&A has occurred in 2026?
Q1 deal value hit $84 billion, according to Dealogic data cited by Reuters. That is nearly double Q1 2025 ($44.4 billion) and the strongest start to a year since 2019. If the pace holds, 2026 could exceed $250 billion in total deal value—second only to 2019.
What is driving the M&A pace?
Structural factors: an estimated $320 billion in patent cliff revenue exposure through 2030, deep cash reserves at large pharma companies, biotech valuations below 2021 highs, and a strong cycle of positive Phase 3 readouts creating de-risked acquisition targets. Three analysts, four investors, and a banker told Reuters the surge is “broader and more durable than just a rebound.”
What is Teva acquiring?
Emalex Biosciences for up to $900 million ($700 million upfront plus $200 million in milestones). Emalex’s lead asset ecopipam is a first-in-class selective dopamine D1 receptor antagonist with positive Phase 3 data in pediatric Tourette syndrome. NDA submission is expected H2 2026. Jefferies called it Teva’s largest deal in a decade.
What makes ecopipam different from current Tourette treatments?
Current dopamine-targeting treatments for Tourette syndrome work through D2 receptor blockade, the same mechanism as antipsychotics, carrying significant side effects including sedation and metabolic complications. Ecopipam selectively targets the D1 receptor, avoiding the D2 pathway entirely. No approved D1-selective treatment currently exists for Tourette syndrome.
What happened to Purdue Pharma?
Purdue permanently ceased operations on May 1 following the conclusion of its Chapter 11 bankruptcy proceedings. Knoa Pharma began operations as the independent successor entity focused on safe medicine access and community support for opioid-affected populations.
How is Foundayo’s launch tracking?
More than 20,000 patients have started the drug per CEO Ricks. IQVIA data show 3,707 prescriptions in Week 2 (ending April 17), up 167% from Week 1 but below analyst expectations of approximately 8,000. Oral Wegovy hit 18,410 in its second full week. Lilly says telehealth channels (35% of volume) may not be fully captured by IQVIA. RBC says Weeks 8 through 12 are the earliest window for true assessment.
When is ASCO?
May 29 through June 2 in Chicago. Revolution Medicines presents full Phase 3 RASolute 302 data in a plenary session on May 31—the most anticipated oncology presentation of the year. The conference will produce data across dozens of programs and is historically a catalyst for M&A discussions.
Which companies have been the most active acquirers in 2026?
Lilly leads with approximately $20 billion across six deals. Gilead committed $15 billion across three Q1 acquisitions. Merck, AbbVie, Novartis, Biogen, UCB, Chiesi, and Teva have all been active. The buyer pool now extends from mega-cap to mid-cap pharma.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The $250B Year: Structural, Not Cyclical. We analyze why the Reuters/Dealogic data confirm a multi-year M&A supercycle rather than a one-quarter spike, map the remaining acquisition capacity across the largest pharma companies, and assess how the ASCO data cycle on May 31 could create the next wave of acquisition targets.
Foundayo vs. Oral Wegovy: Updated Competitive Scorecard. We compile the latest TRx data, launch curve comparisons, telehealth channel dynamics, and IQVIA tracking gaps into a single competitive framework that defines the oral GLP-1 battle heading into Novo’s Q1 earnings.
Teva’s Pivot to Growth: The Emalex Deal in Context. We analyze how ecopipam fits the generics-to-innovation transformation, model the Tourette syndrome commercial opportunity, and assess the synergies with Teva’s existing Austedo neurology franchise.
Plus: ASCO four-week preview, IPO market dynamics, Purdue/Knoa transition implications, and the updated catalyst calendar through ASCO and H2 2026.
About BioMed Nexus
BioMed Nexus delivers institutional-grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep-dive analyses cut through the noise to deliver the strategic insights that drive better decision-making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
